文献速递心力衰竭与心肌病

急性心力衰竭利尿剂联合治疗:系统综述与网络荟萃分析

Combinations of diuretics for acute heart failure: a systematic review with network meta-analysis and trial sequential analysis.
PubMed 文献 · Heart · 2025-11-13

网络荟萃分析和试验序贯分析显示,联合利尿剂可改善短期减淤血(体重下降),但未降低全因死亡率、严重不良事件、再住院或肾衰竭风险。

要点

  • 联合利尿剂改善急性心衰短期减淤血,但不降低全因死亡率。
  • 联合利尿剂未减少严重不良事件、再住院或肾衰竭。
  • 乙酰唑胺、噻嗪类和伐普坦类联合方案显著降低院内体重。

核心结论

  • 联合利尿剂治疗改善急性心衰短期减淤血,但不降低全因死亡率、严重不良事件、再住院或肾衰竭。

研究设计与样本

  • 检索Medline、Embase、LILACS、Web of Science、Scopus和Cochrane Central等数据库。
  • 采用Cochrane RoB 2评估偏倚风险,I²统计量评估异质性,试验序贯分析评估证据充分性。

主要发现

  • 配对荟萃分析中,任何利尿剂对全因死亡率、严重不良事件、再住院或肾衰竭均无影响。
  • 试验序贯分析显示联合治疗对死亡率无影响。
  • 含乙酰唑胺联合方案院内体重下降-2.60 kg(95%CI -4.23至-0.97;p<0.001;I²=0.00%)。
  • 含噻嗪类联合方案院内体重下降-0.80 kg(95%CI -1.40至-0.21;p=0.01;I²=38.53%)。
  • 含伐普坦类联合方案院内体重下降-1.00 kg(95%CI -1.53至-0.48;p<0.001;I²=89.53%)。

关键数值与推荐

  • 主要结局为全因死亡率,次要结局包括严重不良事件、再住院和肾衰竭。
  • 探索性结局包括体重变化和尿量变化。
  • 试验序贯分析提示已有足够信息接受辅助利尿剂影响减淤血。

临床怎么用

  • 急性心衰减淤血治疗中,可考虑联合乙酰唑胺、噻嗪类或伐普坦类以增强短期减淤血效果。
  • 联合利尿剂策略不应以降低死亡率、严重不良事件、再住院或肾衰竭为主要目的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute heart failure (AHF) is a severe clinical syndrome associated with high morbidity and mortality. Effective management of congestion is a primary treatment goal and often requires hospitalisation. While loop-diuretics remain the cornerstone of AHF therapy, the optimal combination of diuretics to an effective decongestion remains uncertain. This systematic review aims to evaluate the efficacy and safety of various diuretic combinations compared with usual care in AHF patients. METHODS: The search was conducted across the databases: Medline, Embase, Latin American and Caribbean Health Sciences Literature, Web of Science, Scopus and The Cochrane Central Register of Controlled Trials. Network meta-analysis was used to compare the relative efficacy of different diuretic combinations. Trial sequential analysis (TSA) was conducted to evaluate the sufficiency of cumulative evidence for definitive conclusions. Risk of bias was assessed using the Cochrane Risk of Bias tool for randomised trials V.2. Statistical heterogeneity was evaluated via visual inspection of forest plots through the I² statistic. The primary outcome was all-cause mortality, and secondary outcomes included serious adverse events (SAEs), hospital readmissions and kidney failure. Exploratory outcomes included changes in body weight and urinary output. RESULTS: 35 randomised clinical trials involving 11 743 patients were included. In pairwise meta-analyses, none of the diuretics demonstrated an influence on all-cause mortality, SAEs, hospital readmissions or kidney failure. Likewise, TSA showed no influence of combination therapy on mortality. Aggregate data meta-analyses revealed that combinations involving acetazolamide (-2.60 kg; 95% CI -4.23 to -0.97; p<0.001; I2=0.00%), thiazides (-0.80 kg; 95% CI -1.40 to -0.21; p=0.01; I2=38.53%) and vaptans (-1.00 kg; 95% CI -1.53 to -0.48; p<0.001; I2=89.53%) caused significant in-hospital body weight reduction, indicating enhanced decongestion. Network meta-analysis showed similar results, and TSA indicated that there was enough information to accept secondary diuretics influencing decongestion. CONCLUSIONS: Combination diuretic therapy improves short-term decongestion but does not reduce all-cause mortality, SAEs, hospital readmissions or kidney failure in patients with AHF.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Nahiz, Jakobsen, Lukoschewitz, et al. Combinations of diuretics for acute heart failure: a systematic review with network meta-analysis and trial sequential analysis. Heart. 2025. PMID: 41233172. doi:10.1136/heartjnl-2025-326601

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。